Ilgiz Rakhmatullin

Senior International Medical Manager
Novo Nordisk A/S
Bagsværd, Hovedstaden, Denmark

Presentation(s):

• LB 01.5 - Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study

  Sunday, June 23, 2024
  10:30 – 10:45 ICT